Halia Therapeutics Announces Presentation at the BIO Investment & Growth Summit
March 03, 2026
LEHI, Utah, March 2, 2026 /PRNewswire/ -- Halia Therapeutics, a clinical-stage biopharmaceutical company advancing therapies grounded in human biology, today announced that it will deliver a company presentation at the BIO Investment & Growth Summit.
David Bearss, Ph.D., Chief Executive Officer of Halia Therapeutics, will present an overview of the company's strategy, platform, and clinical programs.
Presentation Details
Event: BIO Investment & Growth Summit
Date/Time: Monday, March 2, 2026 at 2:30 PM
Location: Ballroom I, Salon C
About NEK7
NEK7 is a critical regulator of inflammasome activation and a required component for assembly and activation of the NLRP3 inflammasome. Activation of this pathway can drive the release of proinflammatory cytokines, including IL-1β and IL-18, contributing to chronic inflammation across hematology, cardiometabolic, pain, and other inflammation-driven diseases. Targeting NEK7 offers a pathway-level approach to modulating NLRP3 inflammasome activity upstream, providing a differentiated strategy versus blocking individual downstream cytokines.
About Halia Therapeutics
Halia Therapeutics is a biotechnology company developing first-in-class inflammasome inhibitors. We target the root causes of inflammation-driven diseases to create transformative therapies.
Media Contact
Taylor Avei
Director of Business Development
Halia Therapeutics
info@haliatx.com
SOURCE Halia Therapeutics
AAPR aggregates press releases and media statements from around the world to assist our news partners with identifying and creating timely and relevant news. All of the press releases published on this website are third-party content and AAP was not involved in the creation of it. Read the full terms.
